<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02310997</url>
  </required_header>
  <id_info>
    <org_study_id>UCL/09/0128</org_study_id>
    <secondary_id>2009-011818-21</secondary_id>
    <nct_id>NCT02310997</nct_id>
  </id_info>
  <brief_title>Myloablative Cord Blood Transplant in Haematological Malignancies (MAC UCBT)</brief_title>
  <acronym>MAC UCBT</acronym>
  <official_title>Transplantation Of Umbilical Cord Blood From Unrelated Donors In Patients With Haematological Diseases Using A Myeloablative Conditioning Regimen</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University College, London</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Cancer Research UK</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University College, London</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial is looking at using umbilical cord blood from unrelated donors after high dose&#xD;
      chemotherapy. It is for people who have cancer of the bone marrow or lymphatic system&#xD;
      including leukaemia and lymphoma, or a blood disorder called myelodysplastic syndrome (MDS).&#xD;
&#xD;
      The trial is for babies over 4 weeks old, children, and adults up to the age of 45.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      During treatment for cancers of the bone marrow or lymphatic system, a lot of the stem cells&#xD;
      are damaged and you may need a bone marrow or stem cell transplant to replace them.&#xD;
&#xD;
      Stem cells can also be collected from the umbilical cord of newborn babies. Many people&#xD;
      around the world have donated their baby's umbilical cords which are stored safely.&#xD;
&#xD;
      There are usually enough cells in one cord to transplant a small child, but there may not be&#xD;
      enough cells for an older child or adult. Researchers want to see if adults and children can&#xD;
      safely have stem cells from more than 1 umbilical cord.&#xD;
&#xD;
      Before a transplant, you have high doses of chemotherapy, sometimes with radiotherapy. This&#xD;
      intensive conditioning aims to destroy all the cells in your bone marrow, and is called&#xD;
      myeloablative conditioning.&#xD;
&#xD;
      The aim of this trial is to see if a transplant using cord blood cells from unrelated donors&#xD;
      after myeloablative conditioning is safe, and whether it helps people who need a stem cell&#xD;
      transplant but don't have a stem cell donor.&#xD;
&#xD;
      You may be able to enter this trial if you:&#xD;
&#xD;
        -  Have leukaemia, lymphoma or another disorder of the bone marrow and treatment with&#xD;
           intensive conditioning followed by a stem cell transplant is likely to help you&#xD;
&#xD;
        -  Do not have a suitable stem cell donor in your family, and your doctors have not been&#xD;
           able to find a matched unrelated donor&#xD;
&#xD;
        -  Have satisfactory blood test results&#xD;
&#xD;
        -  Are between 4 weeks and 45 years old&#xD;
&#xD;
      You cannot enter this trial if you:&#xD;
&#xD;
        -  Have a family member who could donate stem cells to you, or you have a matched unrelated&#xD;
           donor&#xD;
&#xD;
        -  Can have any other treatment that your doctors think will cure your disease or keep it&#xD;
           under control for a long time&#xD;
&#xD;
        -  Have already had a lot of radiotherapy (the trial doctor can advise you about this)&#xD;
&#xD;
        -  Have already had a bone marrow or stem cell transplant using your own cells&#xD;
&#xD;
        -  Have chronic myeloid leukaemia that is in chronic phase and is responding to imatinib,&#xD;
           or is in blast phase and is not responding to treatment Have acute lymphoblastic&#xD;
           leukaemia that is not responding to treatment or has come back and more than 5% of your&#xD;
           bone marrow is made up of immature cells (blasts)&#xD;
&#xD;
        -  Have acute myeloid leukaemia that is not responding to treatment or has come back and&#xD;
           more than 20% of your bone marrow is made up of immature cells (blasts)&#xD;
&#xD;
        -  Have a disease that has come back and you are having another type of treatment (salvage&#xD;
           treatment) but your disease is not responding or is getting worse&#xD;
&#xD;
        -  Have a blood disorder called myelofibrosis&#xD;
&#xD;
        -  Have a blood disorder called aplastic anaemia&#xD;
&#xD;
        -  Have an infection that cannot be controlled with medication&#xD;
&#xD;
        -  Have either the HIV or HTLV virus&#xD;
&#xD;
        -  Are pregnant or breastfeeding&#xD;
&#xD;
      This phase 2 trial aims to recruit 60 people. It will include both adults and children.&#xD;
      Everybody taking part will have intensive conditioning before having a transplant of stem&#xD;
      cells from the umbilical cord blood of at least 1 unrelated donor.&#xD;
&#xD;
      To take part in this trial, the researchers need to be sure that there are 2 lots of cord&#xD;
      blood cells that would be suitable for you. They will only use cells from 2 cords if there is&#xD;
      some concern that they won't get enough cells from 1 umbilical cord.&#xD;
&#xD;
      People aged between 2 and 45 (apart from children under the age of 16 who have acute myeloid&#xD;
      leukaemia, juvenile myelomonocytic leukaemia (JMML) or MDS) will have conditioning with&#xD;
      fludarabine, cyclophosphamide and radiotherapy to the whole body (total body irradiation).&#xD;
      This takes 9 days all together. On the last day, you have the stem cells through a drip into&#xD;
      a vein.&#xD;
&#xD;
      Children under 2 years of age (and children up to the age of 16 who have acute myeloid&#xD;
      leukaemia, JMML or MDS) will have conditioning with busulfan, cyclophosphamide and melphalan.&#xD;
      They do not have radiotherapy. This conditioning takes 10 days all together. They have the&#xD;
      stem cells through a drip into a vein on the 11th day.&#xD;
&#xD;
      The stem cells find their way into your bone marrow where they will start making new blood&#xD;
      cells.&#xD;
&#xD;
      You will see the trial team and have some tests before you start treatment. The tests&#xD;
      include:&#xD;
&#xD;
        -  Physical examination&#xD;
&#xD;
        -  Blood tests&#xD;
&#xD;
        -  Chest X-ray&#xD;
&#xD;
        -  Lung function tests&#xD;
&#xD;
        -  Heart trace (ECG)&#xD;
&#xD;
        -  Heart ultrasound (echocardiogram) or MUGA scan&#xD;
&#xD;
        -  Bone marrow test When you have your treatment, you will be in hospital for about 4 to 6&#xD;
           weeks. As you will be at a high risk of infection, you will be in your own room. This is&#xD;
           called being in isolation. You have another bone marrow test a month after your&#xD;
           transplant.&#xD;
&#xD;
      When you go home, you have to go back to the hospital for regular blood tests. This is likely&#xD;
      to be 2 or 3 times a week to begin with. You may have to go back into hospital for a few days&#xD;
      at some point.&#xD;
&#xD;
      After a transplant, you will see the doctors and have blood tests At least once a week for&#xD;
      the first 3 months At least once a month for the rest of the first year The trial doctors&#xD;
      will follow your progress closely for at least 2 years.&#xD;
&#xD;
      The main side effect of the treatment you have just before the transplant is a drop in the&#xD;
      number of blood cells, causing an increased risk of infection, tiredness and breathing&#xD;
      problems.&#xD;
&#xD;
      We have more information about fludarabine, cyclophosphamide, busulfan and melphalan in our&#xD;
      cancer drugs section.&#xD;
&#xD;
      It takes longer for blood cells to start growing again after a transplant of cord blood than&#xD;
      after other types of stem cell transplant. Even when your blood count gets back to normal,&#xD;
      your immune system may take up to 2 years to recover fully.&#xD;
&#xD;
      Unfortunately, this treatment can affect your ability to have children (your fertility). Men&#xD;
      taking part will be offered the option to store sperm (sperm banking) before starting&#xD;
      treatment. Preserving fertility for women is more complicated and it is important that women&#xD;
      talk to their doctors about this before starting treatment.&#xD;
&#xD;
      After any type of bone marrow or stem cell transplant, there is a risk of graft versus host&#xD;
      disease (GVHD). This happens when the new stem cells attack your body tissue. It mainly&#xD;
      affects your skin, gut and liver.&#xD;
&#xD;
      Rarely, the new stem cells fail to start working. This is more common with cord blood&#xD;
      transplants than with other bone marrow transplants. And even if your transplant is&#xD;
      successful, there is a risk your disease may come back. Because of these risks, your doctors&#xD;
      will monitor you very closely after your transplant.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Trial closed early due to poor recruitment&#xD;
  </why_stopped>
  <start_date>July 2011</start_date>
  <completion_date type="Actual">May 2015</completion_date>
  <primary_completion_date type="Actual">May 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Non-relapse mortality at 100 days post transplant</measure>
    <time_frame>100 days post transplant</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival at 1 year</measure>
    <time_frame>1 year post transplant</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time course of mixed chimerism established by the donor graft</measure>
    <time_frame>28, 60, 100 days, 6 months, 1 year post transplant</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Recovery from neutropenia and cytopenia</measure>
    <time_frame>up to 1 year post transplant</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of acute and chronic GVHD</measure>
    <time_frame>100 Days and 1 year post transplant</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of relapse</measure>
    <time_frame>1 year post transplant</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">11</enrollment>
  <condition>Leukaemia</condition>
  <condition>Lymphoma</condition>
  <condition>Other Haematological Diseases</condition>
  <arm_group>
    <arm_group_label>Fludarabine + Cyclophosphamide + TBI</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients aged 2-45 years (excluding AML, JMML and MDS patients aged &lt;16 years) will receive an umbilical cord blood transplant using a myeloablative conditioning regimen comprising:&#xD;
Fludarabine 25mg/m^2/day day -8 to -6 (total 75mg/m^2) Cyclophosphamide 60mg/kg day -7 and -6 (total 120mg/kg) Total body irradiation 13 - 14.4Gy in 6-8 fractions</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Busulfan + Cyclophosphamide + Melphalan</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients aged &lt; 2 years and AML, JMML and MDS patients &lt;16 years will receive an umbilical cord blood transplant using a myeloablative conditioning regimen comprising:&#xD;
Busulfan 3.2mg/kg/day in 2 or 4 doses per day, days -9 to -6 (total 12.8mg/kg). Cyclophosphamide 60mg/kg days -4 and -3 (total 120mg/kg) Melphalan 140mg/m^2 day -2</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Umbilical Cord Blood Transplant</intervention_name>
    <arm_group_label>Busulfan + Cyclophosphamide + Melphalan</arm_group_label>
    <arm_group_label>Fludarabine + Cyclophosphamide + TBI</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <arm_group_label>Busulfan + Cyclophosphamide + Melphalan</arm_group_label>
    <arm_group_label>Fludarabine + Cyclophosphamide + TBI</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Total body irradiation</intervention_name>
    <arm_group_label>Fludarabine + Cyclophosphamide + TBI</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Busulfan</intervention_name>
    <arm_group_label>Busulfan + Cyclophosphamide + Melphalan</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Melphalan</intervention_name>
    <arm_group_label>Busulfan + Cyclophosphamide + Melphalan</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fludarabine</intervention_name>
    <arm_group_label>Fludarabine + Cyclophosphamide + TBI</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subjects must be &lt; 45 years of age and â‰¥ 28 days old&#xD;
&#xD;
          -  Patients with high risk, advanced or poorly responding haematological disease for&#xD;
             which there is published evidence that haematopoietic stem cell transplantation using&#xD;
             myeloablative conditioning is likely to be effective&#xD;
&#xD;
          -  The individual patient's disease status is such that there is no alternative therapy&#xD;
             likely to achieve cure or provide a significant prolongation of disease-free survival&#xD;
&#xD;
          -  Left ventricular ejection fraction &gt;45%&#xD;
&#xD;
          -  Transaminases and bilirubin &lt; twice the upper limit of the normal range&#xD;
&#xD;
          -  Creatinine clearance &gt; 60mls/min&#xD;
&#xD;
          -  Comorbidity index of 0 or 1&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with a suitably matched sibling donor or 10/10 unrelated volunteer donor&#xD;
             available within an acceptable time period.&#xD;
&#xD;
          -  Pregnancy or breastfeeding.&#xD;
&#xD;
          -  Evidence of HIV or HTLV (I+II) infection or known HIV or HTLV positive serology&#xD;
&#xD;
          -  Current active serious infection, in particular uncontrolled fungal infection&#xD;
             -Previous irradiation that precludes the safe administration of an additional dose of&#xD;
             13- 14.4 Gy of total body irradiation (TBI) in patients aged 2-45 years&#xD;
&#xD;
          -  Prior autograft&#xD;
&#xD;
          -  CML in first chronic phase responding to Imatinib or refractory blast crisis&#xD;
&#xD;
          -  Patients with acute leukaemia in morphological relapse/ persistent disease (defined as&#xD;
             &gt; 5% blasts in normocellular bone marrow)&#xD;
&#xD;
          -  Patients with acute myeloid leukaemia with relapse/persistent disease unresponsive to&#xD;
             re-induction chemotherapy (defined as &gt;20% blasts in normocellular bone marrow)&#xD;
&#xD;
          -  Malignant disease that is refractory to or progressive on salvage therapy&#xD;
&#xD;
          -  Myelofibrosis.&#xD;
&#xD;
          -  Aplastic anaemia&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rachael Hough</last_name>
    <role>Principal Investigator</role>
    <affiliation>University College London Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University College London Hospital</name>
      <address>
        <city>London</city>
        <state>Greater London</state>
        <zip>W1T 4TJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Birmingham</name>
      <address>
        <city>Birmingham</city>
        <zip>B15 2TH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bristol Haematology &amp; Oncology Centre</name>
      <address>
        <city>Bristol</city>
        <zip>BS2 8ED</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Addenbrooke's Hospital</name>
      <address>
        <city>Cambridge</city>
        <zip>CB2 0QQ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St James' University Hospital</name>
      <address>
        <city>Leeds</city>
        <zip>LS9 7TF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St Bartholomew's Hospital</name>
      <address>
        <city>London</city>
        <zip>EC1A 7BE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Great Ormond Street Hospital for Children</name>
      <address>
        <city>London</city>
        <zip>WC1N 3JH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Manchester Royal Infirmary</name>
      <address>
        <city>Manchester</city>
        <zip>M13 9WL</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Christie Hospital NHS Foundation Trust</name>
      <address>
        <city>Manchester</city>
        <zip>M20 4BX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nottingham City Hospital</name>
      <address>
        <city>Nottingham</city>
        <zip>NG5 1PB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Hallamshire Hospital</name>
      <address>
        <city>Sheffield</city>
        <zip>S10 2JF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Marsden Hospital</name>
      <address>
        <city>Sutton</city>
        <zip>SM2 5PT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>May 2015</verification_date>
  <study_first_submitted>September 18, 2014</study_first_submitted>
  <study_first_submitted_qc>December 4, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 8, 2014</study_first_posted>
  <last_update_submitted>May 26, 2015</last_update_submitted>
  <last_update_submitted_qc>May 26, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 27, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Melphalan</mesh_term>
    <mesh_term>Busulfan</mesh_term>
    <mesh_term>Fludarabine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

